Abacus Medicine Pharma Services (AMPS) and Gen.Orph are proud to announce the signing of a partnership agreement for the exclusive marketing and distribution of Miglustat Gen.Orph in Austria.
Miglustat Gen.Orph 100 mg hard capsules is indicated for the oral treatment of mild to moderate type 1 Gaucher disease in adult patients. It must only be used to treat patients for whom enzyme replacement therapy is not an option. In addition, Miglustat Gen.Orph is indicated for the treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Pick type C disease.
Miglustat Gen.Orph has obtained reimbursement for both indications and is positioned in the yellow-box according to the Erstattungskodex (list of reimbursed pharmaceutical products).
Simon Estcourt, Managing Director of Abacus Medicine Pharma Services explains, “This is an exciting opportunity for both companies as it unlocks new geographies for Gen.Orph making the alternative treatment option available to patients and prescribers.”
